Nuclear Receptors in the Etiology and Treatment of Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 December 2024 | Viewed by 1247
Special Issue Editors
Interests: effects of oncogenic kinase signaling on estrogen receptor signaling in breast cancer
Special Issue Information
Dear Colleagues,
Since the discovery of estrogen ablative therapy as a treatment model for breast cancer in the 19th century, targeting of nuclear receptors has been an effective strategy for the management of cancer. However, these strategies are imperfect, as the same receptor signaling mechanisms that promote the deranged cellular functions in cancer are also responsible for the governance of physiological homeostasis in non-transformed tissues. In addition, de novo or acquired resistance to these therapies remains a significant clinical hurdle. Mechanisms ranging from posttranslational modification of receptors, cross-talk with oncogenic kinases, expression of alternative receptor isoforms, and development of point mutations are only a few of the mechanisms that have been suggested to contribute to the oncogenic potential of nuclear receptors, as well as to the therapeutic failure of nuclear receptor-targeting drugs.
Here, we seek to provide a platform for the dissemination of the latest findings around how nuclear receptor signaling impacts the progression of cancer, and how the understanding of these mechanisms might be exploited. We are pleased to invite you to submit your original article or review to this Special Issue of Cancers. We welcome your submissions on any topic relevant to nuclear receptors in cancer, including disease etiology, clinical pathology and prognosis, molecular mechanisms, drug targeting, endocrine disruption, and beyond.
We look forward to receiving your contribution.
Dr. Christopher C. Williams
Dr. Syreeta L. Tilghman
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- estrogen
- progesterone androgen
- testosterone
- nuclear receptor
- breast
- ovarian
- prostate
- uterine
- cancer
